HC Wainwright Reaffirms “Buy” Rating for Checkpoint Therapeutics (NASDAQ:CKPT)

Checkpoint Therapeutics (NASDAQ:CKPT)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports. They currently have a $20.00 price objective on the stock. HC Wainwright’s price objective would indicate a potential upside of 483.09% from the company’s current price.

Checkpoint Therapeutics Stock Performance

Shares of NASDAQ CKPT opened at $3.43 on Thursday. The stock has a 50 day moving average price of $2.82 and a 200 day moving average price of $2.34. The stock has a market capitalization of $154.42 million, a PE ratio of -1.86 and a beta of 1.23. Checkpoint Therapeutics has a 52 week low of $1.36 and a 52 week high of $3.97.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.08). As a group, research analysts forecast that Checkpoint Therapeutics will post -0.81 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CKPT. Geode Capital Management LLC raised its stake in Checkpoint Therapeutics by 41.2% in the 3rd quarter. Geode Capital Management LLC now owns 427,651 shares of the company’s stock valued at $958,000 after acquiring an additional 124,787 shares during the period. State Street Corp increased its holdings in shares of Checkpoint Therapeutics by 32.2% in the third quarter. State Street Corp now owns 94,424 shares of the company’s stock valued at $212,000 after purchasing an additional 23,000 shares during the last quarter. Walleye Capital LLC bought a new position in shares of Checkpoint Therapeutics in the third quarter valued at about $148,000. Gladstone Institutional Advisory LLC lifted its stake in shares of Checkpoint Therapeutics by 141.4% during the 3rd quarter. Gladstone Institutional Advisory LLC now owns 35,000 shares of the company’s stock worth $78,000 after buying an additional 20,500 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Checkpoint Therapeutics by 160.0% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company’s stock worth $291,000 after buying an additional 80,000 shares during the period. 22.00% of the stock is currently owned by institutional investors and hedge funds.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.